Natesto Reduces Migraine Frequency in Hypogonadal U.S. Males: Multicenter Study
Reading Time: < 1 minute Introduction Migraines afflict approximately 12% of American adults, with men comprising about 6% of sufferers, often experiencing more debilitating auras and chronicity due to undiagnosed hypogonadism. Testosterone deficiency, prevalent in up to 40% of men over 45 in the U.S., correlates with heightened neuroinflammatory responses and vascular dysregulation implicated in migraine pathogenesis. Natesto, an intranasal testosterone gel delivering 11 mg per actuation, offers a novel formulation bypassing transdermal risks like secondary exposure. This article synthesizes emerging evidence from a multicenter U.S. study evaluating Natesto's efficacy in modulating migraine frequency and severity among hypogonadal males, highlighting its potential in integrated neurological...


